| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ACCELERATE – Five years accelerating cancer drug development for children and adolescents
|
Pearson, Andrew D.J.
|
|
|
166 |
C |
p. 145-164
|
artikel
|
| 2 |
Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial
|
Shi, Changying
|
|
|
166 |
C |
p. 176-184
|
artikel
|
| 3 |
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA
|
Remon, Jordi
|
|
|
166 |
C |
p. 112-125
|
artikel
|
| 4 |
A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701
|
Kobayshi, Kazuma
|
|
|
166 |
C |
p. 279-286
|
artikel
|
| 5 |
Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO)
|
Aapro, Matti
|
|
|
166 |
C |
p. 126-133
|
artikel
|
| 6 |
Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma
|
Wu, Yuan-Hung
|
|
|
166 |
C |
p. 208-218
|
artikel
|
| 7 |
Corrigendum to “De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis” [Eur J Cancer 158 (2021) 181–188]
|
Gaillard, T.
|
|
|
166 |
C |
p. 311-312
|
artikel
|
| 8 |
Corrigendum to “Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma” [Eur J Canc 157 (2021) 250–258]
|
Baggi, Alice
|
|
|
166 |
C |
p. 309-310
|
artikel
|
| 9 |
Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors
|
Paulet, Lola
|
|
|
166 |
C |
p. 87-99
|
artikel
|
| 10 |
Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis
|
Kroese, Tiuri E.
|
|
|
166 |
C |
p. 254-269
|
artikel
|
| 11 |
Denosumab related osteonecrosis of the jaw: Unusual pattern with periosteal reaction
|
Tagliamento, Marco
|
|
|
166 |
C |
p. 33-37
|
artikel
|
| 12 |
Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients
|
van Mackelenbergh, Marion T.
|
|
|
166 |
C |
p. 185-201
|
artikel
|
| 13 |
Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitors
|
Chang, Michael S.
|
|
|
166 |
C |
p. 21-23
|
artikel
|
| 14 |
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment
|
Lodde, Georg C.
|
|
|
166 |
C |
p. 60-72
|
artikel
|
| 15 |
Histologic transformation of epidermal growth factor receptor–mutated lung cancer
|
Fujimoto, Daichi
|
|
|
166 |
C |
p. 41-50
|
artikel
|
| 16 |
Impact of diabetes and metformin use on recurrence and outcome in stage II–III colon cancer patients—A pooled analysis of three adjuvant trials
|
Christou, Niki
|
|
|
166 |
C |
p. 100-111
|
artikel
|
| 17 |
Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID)
|
Brugel, Mathias
|
|
|
166 |
C |
p. 8-20
|
artikel
|
| 18 |
Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla™ EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib
|
O'Sullivan, Hazel
|
|
|
166 |
C |
p. 38-40
|
artikel
|
| 19 |
Incidence, treatment and relative survival of early-onset colorectal cancer in the Netherlands since 1989
|
Swartjes, Hidde
|
|
|
166 |
C |
p. 134-144
|
artikel
|
| 20 |
Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments
|
Cortés, Alfonso
|
|
|
166 |
C |
p. 229-239
|
artikel
|
| 21 |
Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort
|
Baldacci, Simon
|
|
|
166 |
C |
p. 51-59
|
artikel
|
| 22 |
MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study
|
Salzmann, Martin
|
|
|
166 |
C |
p. 24-32
|
artikel
|
| 23 |
Melanoma in pregnancy: Diagnosis and management in early-stage and advanced disease
|
Carter, Thomas J.
|
|
|
166 |
C |
p. 240-253
|
artikel
|
| 24 |
Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study
|
Rizzato, Mario
|
|
|
166 |
C |
p. 165-175
|
artikel
|
| 25 |
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis
|
Giugliano, Federica
|
|
|
166 |
C |
p. 202-207
|
artikel
|
| 26 |
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
|
Gelber, Richard D.
|
|
|
166 |
C |
p. 219-228
|
artikel
|
| 27 |
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer
|
Delaloge, Suzette
|
|
|
166 |
C |
p. 300-308
|
artikel
|
| 28 |
Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer
|
Derksen, Jeroen W.G.
|
|
|
166 |
C |
p. 73-86
|
artikel
|
| 29 |
Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials
|
Banna, Giuseppe Luigi
|
|
|
166 |
C |
p. 287-299
|
artikel
|
| 30 |
Treatment of patients with stage I focal anaplastic and diffuse anaplastic Wilms tumour: A report from the SIOP-WT-2001 GPOH and UK-CCLG studies
|
Mifsud, William
|
|
|
166 |
C |
p. 1-7
|
artikel
|
| 31 |
When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay
|
Mukherjee, Aritra
|
|
|
166 |
C |
p. 270-278
|
artikel
|
Tijdschrift beschrijving